All In Biotech

Investigational drug · Phase 3

000 MM09

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic.

Phase 3

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

0

Any phase or sponsor naming "000 MM09"

First trial start

2020

Oct 6, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "000 MM09", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Rhinitis, Allergic
  • Rhinoconjunctivitis
  • Asthma, Allergic
  • Allergic Rhinitis
  • Allergic Asthma
  • Allergic Rhinoconjunctivitis
  • Allergy to House Dust Mite

Approved drugs for the same conditions: Asthma · Allergies (allergic rhinitis) · Respiratory · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "000 MM09" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Rhinitis, Allergic

  • 000 MG01Phase 32 trials

    Inmunotek S.L. · Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.